Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter

November 2013 Issue of The Ophthalmologist

Register to download
Register here to download any issue of The Ophthalmologist for FREE.
Login
Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Articles featured in this issue

Business & Profession Business and Innovation

Improvement and Innovation

| Richard Gallagher

One of the most striking aspects of ophthalmology has been the intensity of manufacturers’ stated commitment to innovation.

Subspecialties Glaucoma

Blindingly Obvious Progress

| Mark Hillen

Analysis of a rich long-term epidemiological dataset reveals that interventions have significantly reduced the probability of open-angle glaucoma-related blindness

Subspecialties Glaucoma

The Pill and Glaucoma

| Richard Gallagher

Two studies have found a link between long-term usage of contraceptive pills and glaucoma

Subspecialties Business and Innovation

Smart(phone) Ophthalmoscopy

| Mark Hillen

An iPhone, an app, and a 20 D lens, along with a bit of practice, will get you fundus photographs in a pinch

Business & Profession Other

Do Something, Diabetics!

| Mark Hillen

The AAO are encouraging diabetics to do something to protect their vision: visit their opthalmologist.

Business & Profession Professional Development

Big Pharma Loves Ophtho Even More

| Mark Hillen

Yet more ophthalmology acquisitions and licensing deals were announced this month

Subspecialties Retina

Gazing into the MYRROR

| Mark Hillen

Bayer and Regeneron have presented the phase III trial data for aflibercept treatment of myopic choroidal neovascularization

Business & Profession Health Economics and Policy

Myopia Dystopia

| Richard Gallagher

Five questions that must be answered on the causes and consequences of near-sightedness.

Subspecialties Retina

Loss of Traction

| Mark Hillen

If you had VMT or MH and could avoid vitrectomy, you would. Might ocriplasmin let you?

Subspecialties Retina

Predicting Anti-VEGF Treatment Outcomes

| Sebastian Waldstein

Predicting treatment outcomes manages their expectations and improves your care.

Subspecialties Retina

Treating Macular Edema Following RVO

| Marianne Shahsuvaryan

The last decade has seen some great advances, but there's still room for improvement…

Business & Profession Basic & Translational Research

Stem Cell Clinical Trials

| Irv Arons, Mark Hillen

Therapies based on stem cell treatments are considered to have tremendous potential in medicine.

Business & Profession Professional Development

DIY Market Research

| Kristine Morrill

Market research requires that you examine three things: customers, the competition and the environment.

Business & Profession Professional Development

Does the Patient Know Who You Are?

| Sophia Ktori

Patients need to know what their ophthalmologist actually ‘does’, and what to expect when they are referred.

Business & Profession Other

The Lore of Levofloxacin

Expert opinion: infection prevention & treatment in photorefractive surgery patients.

Subspecialties Retina

Achieving Consensus on the Treatment of DME with ILUVIEN®

Who should receive ILUVIEN® for the treatment of chronic DME-associated vision impairment

Business & Profession Professional Development

When Physics is Your Friend

Jim discusses his background, leadership style and his vision for Oraya's future with us.

Other issues of 2013